ArticleScientific reports2018
Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 92 citations in OpenAlex.
- The central amygdala gates exogenous glucagon-like peptide 1 signals.Molecular metabolism · 2026Article
- Article
- Article
- Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.Obesity science & practice · 2026Review
- GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug.Frontiers in pharmacology · 2026Article
- Topiramate Enhances GABAergic Tone to Orexigenic Neuropeptide Y/Agouti-Related Peptide (NPY/AgRP) Neurons.Obesity (Silver Spring, Md.) · 2026Article
- Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.Frontiers in endocrinology · 2026Article
- The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism.Diabetes, obesity & metabolism · 2026Article
- The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.Frontiers in endocrinology · 2026Article
- Brain-Derived GLP-1-Understanding the Physiological Function and Anti-obesity Potential of Preproglucagon Neurons.Endocrinology · 2025Review
- Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.Molecular metabolism · 2025Article
- Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?Biomedicines · 2025Article
- The Duke Mouse Brain Atlas: MRI and light sheet microscopy stereotaxic atlas of the mouse brain.Science advances · 2025Article
- Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.Basic & clinical pharmacology & toxicology · 2025Review
- Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.Neuropharmacology · 2025Review
- GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.Endocrinology · 2025Review
- Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala.Endocrinology · 2025Review
- Novel neural pathways targeted by GLP-1R agonists and bariatric surgery.Pflugers Archiv : European journal of physiology · 2025Review
- Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart.Comprehensive Physiology · 2025Review
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Light Sheet Fluorescence Microscopy (LSFM) of whole organs, in particular the brain, offers a plethora of biological data imaged in 3D. This technique is however often hindered by cumbersome non-automated analysis methods. Here we describe an approach to fully automate the analysis by integrating with data from the Allen Institute of Brain Science (AIBS), to provide precise assessment of the distribution and action of peptide-based pharmaceuticals in the brain. To illustrate this approach, we examined the acute central nervous system effects of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide. Peripherally administered liraglutide accessed the hypothalamus and brainstem, and led to activation in several brain regions of which most were intersected by projections from neurons in the lateral parabrachial nucleus. Collectively, we provide a rapid and unbiased analytical framework for LSFM data which enables quantification and exploration based on data from AIBS to support basic and translational discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.